Recent News

• 03.04.2025 - MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
• 12.19.2024 - MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company’s Pipeline Development
• 12.10.2024 - MIRA Pharmaceuticals Validates Ketamir-2’s Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
• 11.20.2024 - MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

Recent Filings

• 03.04.2025 - 8-K Current report
• 12.20.2024 - 8-K Current report
• 12.19.2024 - 8-K Current report
• 12.10.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.10.2024 - 8-K Current report
• 12.10.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.10.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.10.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.10.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.10.2024 - 4 Statement of changes in beneficial ownership of securities